Actively Recruiting
Aspirin Use for Gastric Cancer Prevention in the Early Gastric Cancer Patients
Led by National Cancer Center, Korea · Updated on 2024-12-27
1700
Participants Needed
10
Research Sites
632 weeks
Total Duration
On this page
Sponsors
N
National Cancer Center, Korea
Lead Sponsor
I
Incheon St.Mary's Hospital/The Catholic University
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aimed to investigate the effect of low-dose (100 mg) asprin on the prevention of gastric cancer in the early gastric cancer patients with negative H. pylori status who underwent endoscopic submucosal dissection.
CONDITIONS
Official Title
Aspirin Use for Gastric Cancer Prevention in the Early Gastric Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women aged 19 to 70 years who underwent endoscopic resection for high-grade adenoma or early gastric cancer
- Final pathology after endoscopic resection meets absolute or expanded criteria per Japanese Gastric Cancer Treatment guideline 2014
- Negative Helicobacter pylori status or successfully eradicated H. pylori
- Willingness to sign informed consent form
You will not qualify if you...
- Aspirin use for secondary prevention of cardiovascular or cerebrovascular diseases
- Regular aspirin use (more than 3 times a week) within 2 months before screening
- Use of anticoagulants or antiplatelet drugs for therapy
- History of gastrectomy
- Serious medical conditions hindering participation (severe heart dysfunction, liver cirrhosis, renal failure, COPD, bronchial asthma, uncontrolled infection)
- High risk for bleeding complications (cerebral aneurysm, vascular malformation, esophageal or gastric varices, hemophilia, etc)
- Active peptic ulcer disease (patients with completely treated peptic ulcer may enroll)
- Diagnosis and active treatment of other organ cancers within 5 years (except carcinoma in situ and non-melanoma skin cancer)
- Non-curative resection of early gastric cancer after endoscopic resection
- Aspirin allergy or contraindication
- Pregnant or lactating women
- Alcoholism or drug abuse
- Unfit for study enrollment as evaluated by study physician
- Inability to provide informed consent
- Took less than 80% of 28-day run-in period medication
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 10 locations
1
Pusan National University Hospital
Busan, South Korea, 49241
Actively Recruiting
2
Kosin University Gospel Hospital
Busan, South Korea, 49267
Actively Recruiting
3
Hallym University Chuncheon Sacred Heart Hospital
Chuncheon, South Korea, 24253
Actively Recruiting
4
Kyungpook National University Chilgok Hospital
Daegu, South Korea, 41404
Actively Recruiting
5
National Cancer Center
Goyang, South Korea, 10408
Actively Recruiting
6
Chonnam National University Hospital
Gwangju, South Korea, 61469
Actively Recruiting
7
Incheon St.Mary's Hospital/The Catholic University
Incheon, South Korea, 21431
Actively Recruiting
8
Chung-Ang University Hospital
Seoul, South Korea, 06973
Actively Recruiting
9
SMG-SNU Boramae Medical Center
Seoul, South Korea, 07061
Actively Recruiting
10
Asan Medical Center
Seoul, South Korea
Not Yet Recruiting
Research Team
I
Il Ju Choi, M.D., Ph.D.
CONTACT
Y
Young-Il Kim, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here